Results 11 to 20 of about 180,091 (130)

Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration. [PDF]

BMJ Open Ophthalmol, 2022
Aim To compare outcome between patients treated using a modified treat-and-extend (mT&E) protocol and patients treated using a conventional T&E protocol. Methods A retrospective cohort study of two groups of treatment-naïve neovascular age ...
Vofo BN, Cnaany Y, Chowers I.
europepmc   +4 more sources

Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy [PDF]

Ophthalmology and Therapy, 2023
Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical ...
Chu-Hsuan Huang, Tso-Ting Lai, Chang-Hao Yang, Yi-Ting Hsieh   +3 more
doaj   +2 more sources

Five-year outcome of aflibercept intravitreal injection in naïve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen: Results from a prospective observational study [PDF]

Taiwan Journal of Ophthalmology, 2023
PURPOSE: The purpose is to study the 5-year results of aflibercept monotherapy using an individualized regimen in naïve patients with neovascular AMD (nAMD). MATERIALS AND METHODS: This is a prospective observational study including naïve nAMD patients
Jarret Charles, TRAN Thi Ha Chau
doaj   +2 more sources

Aflibercept for central retinal vein occlusions: long-term outcomes of a 'Treat-and-Extend' regimen. [PDF]

BMJ Open Ophthalmol
Background/aims This study reports on the long-term functional and anatomical outcomes of patients with central retinal vein occlusion (CRVO) treated under the Bern treat-and-extend (T&E) protocol. Methods Observational study.
Jaggi D, Nagamany T, Wolf S, Zinkernagel MS, Heussen FM.   +4 more
europepmc   +4 more sources

Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up [PDF]

Clinical Ophthalmology
Taras B Kustryn, Oleg S Zadorozhnyy, Illia O Nasinnyk, Alla O Nevska, Kseniia V Troianovska, Nataliya V Pasyechnikova, Andrii R Korol Laser Microsurgery Department, The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of ...
Kustryn TB, Zadorozhnyy OS, Nasinnyk IO, Nevska AO, Troianovska KV, Pasyechnikova NV, Korol AR   +6 more
doaj   +2 more sources

External Limiting Membrane Disruption Predicts Long-Term Outcome in Strict Treat-And-Extend Regimen in Neovascular Age-Related Macular Degeneration

Frontiers in Medicine, 2021
The use of anti-vascular-endothelial growth factor agents for neovascular age-related macular degeneration (nAMD) in different treatment schemes is widely common in clinical practice.
Laura Hoffmann, Katja Hatz, Katja Hatz
doaj   +1 more source

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration

International Journal of Retina and Vitreous, 2021
Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration.
Alaa Din Abdin, Asem Mohamed, Cristian Munteanu, Isabel Weinstein, Achim Langenbucher, Berthold Seitz, Shady Suffo   +6 more
doaj   +1 more source

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration

BMC Ophthalmology, 2020
Background To evaluate the three-year outcome after intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD). Methods Forty-nine treatment-naïve nAMD patients (50 eyes) were enrolled in this prospective study.
Kanako Itagaki, Tetsuju Sekiryu, Akihito Kasai, Yukinori Sugano, Masashi Ogasawara, Masaaki Saito   +5 more
doaj   +1 more source

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration

International Journal of Retina and Vitreous, 2021
Purpose To investigate the visual and anatomical outcomes associated with treat-and-extend (TAE) regimen of intravitreal (IVT) aflibercept in eyes with treatment naïve neovascular age-related macular degeneration (nvAMD).
Mohamed Kamel Soliman, Nicolas Tuli, Thomas K. Lee, William A. Britton, Raman Tuli   +4 more
doaj   +1 more source

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Ophthalmology and Therapy, 2020
Aims To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD test) between baseline and 24 months in ...
Praveen J. Patel, Hari Jayaram, Maria Eleftheriadou, Clara Vazquez-Alfageme, Niaz Islam, Gary S. Rubin, Bishwanath Pal, Peter K. Addison, Robin Hamilton, Simona Degli Esposti   +9 more
doaj   +1 more source